tiprankstipranks

Inhibikase Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused following results from the Phase 2 trial. The firm cites the company’s decision to halt further development of risvodetinib for the downgrade.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue